OKYO Pharma Limited ADR OKYO 深 滬
已收盤 12-24 16:00:00 美东时间
2.03
-0.030
-1.46%
華盛通- 最 高2.13
- 今 開2.04
- 成交量 2.14万股
- 最 低 2.013
- 昨 收 2.06
- 總市值 7634.97万
- 52周最高 3.349
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 0.9016
- 委 比 -23.95%
- 總股本 3761.07万
- 歷史最高 7.00
- 量 比 0.40
- 振 幅 5.68%
- 歷史最低 0.8075
- 每 手 1
- 風險率 0.62%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多OKYO Pharma to Ring the Opening Bell at Nasdaq
OKYO Pharma Limited, a clinical-stage biopharmaceutical company developing urcosimod for neuropathic corneal pain (NCP), announced its Executive Chairman Gabriele Cerrone and management will ring the Nasdaq Opening Bell in New York, celebrating the company's advancements in innovative treatments. The ceremony highlights urcosimod, a lipid-conjugated chemerin peptide agonist targeting the ChemR23 receptor, with recent positive Phase 2 results show...
12-19 12:00
OKYO Pharma Chairman Increases Stake Amid Promising Drug Trials
OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has provided an update. On Decemb...
12-15 21:58
OKYO Pharma Announces Chairman and Founder Acquires Shares
OKYO Pharma Limited，专注于眼科药物开发的生物制药公司，宣布其董事长Gabriele Cerrone通过Panetta Partners Limited增持24,551股，使总持股增至10,516,297股。其药物Urcosimod在干眼症和神经性角膜疼痛的二阶段试验中均显示显著疗效，用于治疗这两种慢性眼疾。
12-15 13:30
OKYO Pharma Announces New Analyses Of Corneal Images From Placebo-Controlled, Randomized, Double-Masked, Phase 2 Clinical Trial Of Urcosimod In Neuropathic Corneal Pain
Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo groupThese findings suggest that urcosimod may have a
12-11 21:38
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
OKYO Pharma Announces Chairman and Founder Acquires Shares
OKYO Pharma Limited (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity linked to Gabriele Cerrone, has acquired 27,051 ordinary shares, increasing his total holding to 10,491,746 shares. The company is developing urcosimod, a lipid-conjugated chemerin peptide agonist targeting the ChemR23 receptor, for treating neuropathic corneal pain (NCP) and dry eye disease. Urcosimod has demonstrated anti-inflammatory and pain-reducing effects...
12-03 12:00
OKYO Pharma Announces Chairman and Founder Acquires Shares
OKYO Pharma Limited, a bio-pharmaceutical company focused on ophthalmology, announced that Panetta Partners, an entity connected to Executive Chairman Gabriele Cerrone, acquired 82,018 shares, increasing his total holding to 10,464,695 shares. The company is developing urcosimod, a lipid-conjugated chemerin peptide agonist targeting neuropathic corneal pain (NCP), a condition lacking FDA-approved therapies. Urcosimod has shown anti-inflammatory a...
11-21 13:30
OKYO Pharma to Present at OIS XV in San Diego
OKYO Pharma's CEO, Gary S. Jacob, will present the company's lead drug candidate, urcosimod, at the Ophthalmology Innovation Summit (OIS) XV in San Diego on November 22. Urcosimod is being developed to treat Neuropathic Corneal Pain (NCP), a condition with no FDA-approved therapy. The presentation follows positive Phase 2 trial results showing urcosimod's anti-inflammatory and pain-relieving effects. OKYO is advancing toward a multi-center clinic...
11-18 13:30
OKYO Pharma to Present at BIO-Europe 2025 in Vienna
OKYO Pharma Limited的CEO Gary S. Jacob将在维也纳举行的BIO-Europe会议上介绍其治疗神经性角膜疼痛的主要候选药物urcosimod，并分享第二阶段临床试验的最新进展。该药物已显示抗炎和止痛效果，并已完成针对17例患者的第二阶段试验。公司还将在会议期间与潜在合作伙伴讨论临床数据及发展规划。
10-29 11:00
OKYO Pharma’s Chairman Increases Stake with New Share Acquisition
An announcement from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now avail...
10-16 20:57
